Page 101 - Recognizing axial spondyloarthritis - Janneke de Winter

as well as with disease duration (OR 1.02, p=0.009). Other patient characteristics or SpA features were not associated with HLA-C*07 negativity in the GESPIC axSpA population in the multivariate model.
We next assessed if HLA-C*07 absence was associated with similar phenotypic features in SPACE. Table 2 shows characteristics of axSpA patients positive and negative for HLA-C*07. Of the 28 HLA-C*07-positive patients, 9 were male, compared to 33 of the 66 HLA-C*07-negative axSpA patients (32.1% vs. 50.0%, p=0.11). Eight of the 28 HLA-C*07-positive axSpA patients had psoriasis compared to 5 of the 66 HLA-C*07 negative axSpA patients (28.6% vs. 7.6%, p=0.007). The mean ESR of HLA-C*07 positive patients was 12.0 (SD 12.8) and 21.0 (SD 21.9) in HLA-C*07 negative patients (p=0.02). There were no differences in the prevalence of a positive family history, the duration of back pain, the prevalence of inflammatory back pain (IBP), peripheral arthritis, enthesitis, dactylitis, IBD, uveitis or sacroiliitis on MRI or X-ray between HLA-C*07 positive and negative patients (Table 2). Both a univariate and multivariate logistic regression analysis within the axSpA patients confirmed that psoriasis was conversely correlated with HLA-C*07 negativity (OR 0.20, p=0.013). Other patient characteristics or SpA features were not associated with HLA-C*07 absence or presence in the SPACE axSpA population in the multivariate analysis.
Table 1. Demographic and disease characteristics of HLA-C*07 positive and negative axSpA patients of GESPIC
HLA-C*07 IN AXIAL SPA
Male (n, %)
Age (mean, SD)
HLA-B*27 positive (n, %)
Positive family history of AS (n, %) Duration of back pain in
months (mean, SD)
Peripheral arthritis baseline (n, %) Enthesitis current (n, %)
IBD (n, %)
Psoriasis current (n, %)
Uveitis ever (n, %)
CRP, mg/L (mean, SD)
mNY criteria (n, %)
mSASSS baseline
Sacroiliitis on MRI (n, %)
BASDAI (mean, SD)
Positive (n=65)
26 (40.0%) 37.5 (9.6)
49 (75.4%)
13 (20.0%) 42.4 (SD 27.5)
8 (12.3%) 13 (20.0%) 1 (1.5%) 11 (16.9%) 11 (16.9%) 7.8 (13.9) 31 (47.7%) 3.26 Unknown 3.69
Negative (n=131) p-value
74 (56.5%) .03 37.5 (11.3) .99 109 (83.8%) .16 20 (15.3%) .40 53.7 (±24.4) .02
22 (16.8%) .41 31 (23.7%) .56 3 (2.3%) .73 9 (6.9%) .03 29 (22.1%) .39 12.6 (20.5) .02 82 (62.6%) .047 4.99 .03
3.70 .96
HLA-C*07 in axSpA patients
AxSpA axial Spondyloarthritis, GESPIC GErman SPondyloarthritis Inception Cohort, HLA human leukocyte antigen, AS ankylosing spondylitis, IBD inflammatory bowel disease, CRP C-reactive protein, mNY modified New York, mSASSS modified Stoke Ankylosing
99
SIX